Literature DB >> 15831594

Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.

M E Baser1, V-F Mautner, D M Parry, D G R Evans.   

Abstract

Four longitudinal studies of vestibular schwannoma (VS) growth rates in neurofibromatosis 2 (NF2) have yielded very different results on the relationship of VS growth rates to age. The studies had different patient eligibility criteria, indices of VS growth rates, VS volumetric methods, and sample sizes. We reanalysed data from two of the longitudinal studies and used data from the population based United Kingdom NF2 Registry to determine the most likely reason for the different results and the actual relationship of VS growth rates to age. We found that the eligibility criterion in one study caused selection bias for slower growing VS. The proper interpretation of the results from the four studies is that VS growth rates in NF2 are highly variable but tend to decrease with increasing age. Clinical trials for VS in NF2 should focus on younger patients because VS growth rates tend to decrease with increasing age, and because faster growing VS are more likely to be excised with increasing age than slower growing VS.

Entities:  

Mesh:

Year:  2005        PMID: 15831594      PMCID: PMC1735973          DOI: 10.1136/jmg.2005.031302

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  14 in total

1.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

2.  Determinants of tumor size and growth in vestibular schwannomas.

Authors:  S L Nutik; M J Babb
Journal:  J Neurosurg       Date:  2001-06       Impact factor: 5.115

3.  Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study.

Authors:  Victor-Felix Mautner; Michael E Baser; Sarang D Thakkar; Urs M Feigen; J M Friedman; Lan Kluwe
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

4.  Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.

Authors:  Michael E Baser; Erini V Makariou; Dilys M Parry
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

5.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

6.  The growth rate of acoustic neuromas.

Authors:  K Ogawa; J Kanzaki; S Ogawa; M Yamamoto; S Ikeda; R Shiobara
Journal:  Acta Otolaryngol Suppl       Date:  1991

7.  Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.

Authors:  William H Slattery; Laurel M Fisher; Zarina Iqbal; Mark Oppenhiemer
Journal:  Otol Neurotol       Date:  2004-09       Impact factor: 2.311

8.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

9.  A comparison of growth rates of acoustic neuromas: nonsurgical patients vs. subtotal resection.

Authors:  S I Rosenberg; H Silverstein; M A Gordon; J M Flanzer; T O Willcox; J Silverstein
Journal:  Otolaryngol Head Neck Surg       Date:  1993-09       Impact factor: 3.497

10.  Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases.

Authors:  R A Sobel
Journal:  J Neuropathol Exp Neurol       Date:  1993-03       Impact factor: 3.685

View more
  11 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

3.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

4.  Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2.

Authors:  Shi-Wei Li; Jing Zhang; Han-Lu Tang; Peng Li; Bo Wang; Fu Zhao; Pi-Nan Liu
Journal:  J Neurooncol       Date:  2021-11-09       Impact factor: 4.130

Review 5.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

6.  Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2.

Authors:  Alvin T deTorres; Carmen C Brewer; Chris K Zalewski; Kelly A King; Robert Walker; Gretchen C Scott; Ashok R Asthagiri; Prashant Chittiboina; Hung Jeffrey Kim
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

7.  Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants.

Authors:  Daniel Moualed; Jonathan Wong; Owen Thomas; Calvin Heal; Rukhtam Saqib; Cameron Choi; Simon Lloyd; Scott Rutherford; Emma Stapleton; Charlotte Hammerbeck-Ward; Omar Pathmanaban; Roger Laitt; Miriam Smith; Andrew Wallace; Mark Kellett; Gareth Evans; Andrew King; Simon Freeman
Journal:  Eur J Hum Genet       Date:  2022-01-24       Impact factor: 4.246

8.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

9.  [18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.

Authors:  Jose M Anton-Rodriguez; Daniel Lewis; Ibrahim Djoukhadar; David Russell; Peter Julyan; David Coope; Andrew T King; Simon K L Lloyd; D Gareth Evans; Alan Jackson; Julian C Matthews
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

10.  Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation.

Authors:  Katrina A Morris; John F Golding; Patrick R Axon; Shazia Afridi; Claire Blesing; Rosalie E Ferner; Dorothy Halliday; Raj Jena; Pieter M Pretorius; D Gareth Evans; Martin G McCabe; Allyson Parry
Journal:  Neurooncol Pract       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.